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Abstract
Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies
have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant
clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF)
is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment
associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings
in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of
autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients
treated with this approach.
Introduction
Increasing number of reports support the possibility of
utilizing adult stem cell therapy not only for treatment of
degenerative conditions, but also as a means of addres-
sing underlying inflammation or autoimmune conditions
[1-8]. Unfortunately, stem cell therapy is often compli-
cated by the need for complex laboratories, processing
procedures and clean rooms. The potential drawbacks of
allogeneic donor approaches include the possibility of
eventual rejection of the cellular graft [9-12], as well as
limitation of efficacy due to trophic effects but not de
novo tissue generation [13-15]. Conversely, adult stem
cell based approaches, particularly using bone marrow,
are limited to the relatively small number of progenitor
cells within the bone marrow. While bone marrow
mononuclear cell administration appears to be effective
in conditions where cells are locally implanted, such as
intramyocardial [16-18], or intramuscular in critical limb
ischemia [19-21], the intravenous administration of non-
expanded bone marrow has not been performed with
efficacy in systemic conditions without prior myeloabla-
tion of the recipient. One way of circumventing this pro-
blem is to expand autologous stem cells prior to
implantation. Unfortunately, besides issues of cost and
practicality, there is a risk that the in vitro manipulation
could be linked to contamination, as well as genomic
alterations of the cells, leading to transformation.
Several studies have used bone marrow derived
mesenchymal stem cells (MSC) for various conditions
including type 2 diabetes [22], osteoarthritis [23], stroke
[24], and amyotrophic lateral sclerosis [25]. This proce-
dure requires expansion of the MSC compartment in
vitro and therefore adds an element of complexity to
the treatment. A much simpler procedure, for which
adipose tissue is uniquely suited, is the administration of
autologous, non-expanded cellular fraction. The ratio-
nale behind this derives from observations that: a) adi-
pose tissue contains substantially higher numbers of
MSC compared to bone marrow [26]; b) MSC from adi-
pose tissue do not appear to decrease in number as a
result of age [27,28]; and c) adipose tissue contains
unique populations of cells including high concentra-
tions of endothelial progenitor cells and T regulatory
(Treg) cells that express up to 100-fold higher levels of
the immune suppressive cytokine IL-10 as compared to
circulating Tregs [29].
The adipose stromal vascular fraction (SVF) is com-
prised of the mononuclear cells derived from adipose
t i s s u e .T h i st e r mi sm o r et h a n4d e c a d e so l d ,u s e dt o
describe the mitotically active source of adipocyte pre-
cursors [30,31]. SVF as a source of stem cells was first
described by Zuk et al. who identified MSC-like cells in
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genic, chondrogenic, myogenic, and osteogenic lineages
[32]. Subsequent to the initial description, the same
group reported after in vitro expansion, the SVF derived
cells had surface marker expression similar to bone mar-
row derived MSC, comprising CD29, CD44, CD71,
CD90, CD105/SH2, andSH3 and lacking CD31, CD34,
and CD45 expression [33,34].
Reported clinical trials on adipose derived cells, to
date, have all utilized ex vivo expanded cells, which
share properties with bone marrow derived MSC
[35-40]. MSC expanded from adipose tissue are equiva-
lent, if not superior to bone marrow in terms of differ-
entiation ability [41,42], angiogenesis stimulating
potential [43,44], and immune modulatory effects [45].
Given the requirements and potential contaminations
associated with ex vivo cellular expansion, a simpler
procedure would be the use of primary adipose tissue
derived cells for therapy. Indeed, it is reported that over
4000 horses and 4000 dogs with various cartilage and
bone injuries have been successfully treated with autolo-
gous SVF [46]. In double blind studies of canine
osteoarthritis statistically significant improvements in
lameness, range of motion, and overall quality of life
have been described [47,48].
If such approaches could be translated clinically, an
easy-to-use autologous stem cell therapy could be
implemented that is applicable to a multitude of indica-
tions. Indeed, this is the desire of commercial entities
that are developing bench-top closed systems for autolo-
gous adipose cell therapy [49,50], which are presently
entering clinical trials. Unfortunately, since the majority
of scientific studies have focused on in vitro expanded
adipose derived cells, relatively little is known about the
potential clinical effects of the whole lipoaspirate that
contains numerous cell populations besides MSC. From
a safety perspective the process of autologous fat graft-
ing has been commonly used in cosmetic surgery
[51,52]. Therefore, administration of autologous hetero-
geneous adipose cellular fractions, which contain
numerous cellular populations besides MSC, should be
relatively innocuous. However, from an efficacy or dis-
ease-impact perspective, it is important to consider the
various cellular components of adipose tissue and to
develop a theoretical framework for evaluating activities
that these components may mediate when administered
systemically. For example, while attention is focused on
the MSC component of adipose tissue, the high concen-
trations of monocytes/macrophages, and potential
impact these may have on a clinical indication is often
ignored [29].
In the published literature, the clinical use of systemi-
cally administered SVF cells has been reported in two
pilot studies by our group. The first was a description of
3 patients suffering from multiple sclerosis who received
intravenous administration of autologous adipose SVF
as part of a cellular cocktail. All 3 patients reported sig-
nificant improvement neurologically, and demonstrated
an excellent safety profile [53]. Additionally, a 1 patient
case report described a remission of RA subsequent to
administration of autologous SVF as a monotherapy
[ 2 9 ] .H e r ew ew i l lp r o v i d ead e s c r i p t i o no fa d i p o s eS V F
components, provide a rationale for use, and describe
safety at 1, 3, 6, and 12 months in a 13 patient retro-
spective analysis.
The MSC component of adipose tissue
MSC are conventionally extracted from bone marrow
sources as a cellular therapy for inflammatory associated
conditions. Specifically, the most advanced clinical trials
in the area of regenerative medicine have been per-
formed by the company Osiris, whose main product is a
“universal donor” MSC, termed “Prochymal”[54]. This
cellular product has entered Phase III trials in graft ver-
sus host disease, and is currently being tested for heart
failure [55]. Other bone marrow derived MSC-like pro-
ducts are in clinical trials, for example, Mesoblast is in
Phase III assessing its Mesenchymal Precursor Cell for
efficacy in post hematopoietic transplant graft failure, as
well as in Phase II for heart failure [56]. Therapeutic
advantages of MSC include their ability to migrate to
injured tissue, in part via detections of hypoxia through
the CXCR4-SDF-1 axis [57,58], differentiation activity
into multiple tissues [59,60], release of trophic factors
[61], inhibition of apoptosis [62-64], stimulation of
angiogenesis [65], inhibition of inflammation [66], and
stimulation of Treg activity [67]. Despite the advantages
of the current approaches, bone marrow contains rela-
tively small numbers of MSC, thus, as previously men-
tioned, therapeutics with bone marrow for systemic
applications requires ex vivo expansion. Specifically, the
bone marrow contains approximately 1/10,000 to 1/
100,000 MSC per nucleated cells [68], whereas adipose
tissue contains approximately 100-1000 fold higher
MSC concentration, or approximately 50-100,000 MSC
per ml [69]. Given the relative ease of extracting 500 ml
of lipoaspirate, it is conceptually feasible to generate a
25-50 million cell dose of MSC, which is close to the
systemic doses of MSC that are typically used in clinical
trials of allogeneic expanded cells (eg. 50-100 million
cells in various clinical trials) [34]. Conceptually, given
that the MSC present in the SVF are autologous, one
could envision higher therapeutic potential due to the
lack of allo-immune clearance as compared to allogeneic
MSC, although this needs to be assessed experimentally.
Adipose MSC contain several similarities and differ-
ences as compared to bone marrow derived MSC,
although this area is still considered to be controversial.
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demonstrated that that expanded adipose MSC are
superior to bone marrow MSC in terms of stimulating
angiogenesis, decreasing cardiac pathology, and stimulat-
ing VEGF and FGF secretion [70]. Using an in vivo len-
tiviral-labeled system, it was demonstrated that adipose
derived MSC have a superior ability to BM derived
MSC to integrate into cardiac muscle after injury, as
well as to restore function [71]. In addition to specific
propensities for differentiation, adipose tissue-derived
MSC appear to be superior to bone marrow in terms of
proliferative potential without loss of telomere length.
Vidal et al. demonstrated that adipose MSC could multi-
ply for almost twice as many cell passages without
undergoing senescence as compared to bone marrow
MSC [72].
Conversely, several authors have reported similarities
between bone marrow and SVF MSC sources. For
example, subsequent to exposure to chemotactic agents,
both sources were reported to yield MSC possessing
similar rates of migration [73]. The same study also
demonstrated comparable ability to generate cartilage
when treated under differentiation conditions. Another
s t u d yr e p o r t e de x p o s u r eo fb o n em a r r o wo ra d i p o s e
derived MSC to ischemia leads to the release of similar
levels of angiogenic factors, as well as resistance to
apoptosis when cultured in hypoxic environments [74].
Comparison of immunological properties led to the con-
clusion that when expanded, both BM and adipose
derived MSC appear to have similar properties in terms
of suppressing mixed lymphocyte reactions, inhibiting
release of type 1 and inflammatory cytokines, as well as
generating progeny cells that appear to be relatively
immune privileged [75]. These data were confirmed by
the group of Zhang et al. who compared cord blood,
bone marrow, and adipose MSC and found almost iden-
tical ability to inhibit immune response assays in vitro
[76]. In contrast, Najar et al. reported that Wharton
Jelly and adipose derived MSC were superior immune
suppressors as compared to BM MSC in terms of inhi-
biting lymphocyte proliferation and type 1 cytokine pro-
duction [77,78]. An important consideration is that
there is a great deal of variability between studies, not
only in the tissue sources from which MSC are derived
but also in terms of cell isolation, culture and expansion
methods as well as donor-specific characteristics that
could conceivably influence the activities and differentia-
tion potential of these cells [79]. Therefore, one poten-
tial disadvantage of utilizing ex vivo-manipulated MSC
is the potential for introducing more heterogeneity in
their regenerative capabilities. For treatments involving
autologous MSC, patient-to-patient differences in MSC
function could also lead to variability in the clinical effi-
cacy of treatments.
Clinically, adipose derived MSC have been used in
treatment of 8 spinal cord injury patients in Korea
where administration of autologous expanded MSC at
doses of 400 million per patient did not elicit treatment
associated adverse events during a 3-month follow-up
[80]. Additionally, this study also reported genetic stabi-
lity of MSC in vitro and lack of toxicity or tumorigeni-
city of MSC in immune deficient mice. Trivedi’sg r o u p
treated 11 patients with type 1 diabetes using a combi-
nation of autologous adipose derived MSC that were
cultured in a pro-pancreatic differentiation media
together with cultured bone marrow MSC. No adverse
effects were noted over an average of 23 months follow-
up period and a decrease in insulin requirements was
noted [81]. Garcia-Olmo et al. reported a study where
autologous expanded adipose MSC were administered
to patients with complex perianal fistulas, with 35 of
cryptoglandular origin and 14 associated with Crohn’s
disease. They observed that fistula healing occurred in
17 (71 percent) of 24 patients who received ASCs in
addition to fibrin glue compared with 4 (16 percent) of
25 patients who received fibrin glue alone (relative risk
for healing, 4.43; confidence interval, 1.74-11.27; P <
0.001). The proportion of patients with documented fis-
tula healing was similar in Crohn’s and non-Crohn’s
subgroups. ASCs were also more effective than fibrin
glue alone in patients with a suprasphincteric fistulous
tract (P = 0.001). Furthermore, quality of life scores
were higher in patients who received ASCs than in
those who received fibrin glue alone [82]. Due to the
anti-inflammatory effects of MSC in general [83-86],
and specifically the ability of MSC to inhibit graft versus
host disease (GVHD) [87,88], Fang et al. reported a ser-
ies of pilot cases in which patients with steroid refrac-
tory GVHD was successfully treated by administration
of autologous adipose derived expanded MSC [89,90].
Thus it appears that the MSC component of adipose
tissue possesses numerous preclinical and clinical thera-
peutic properties and may be an important component
of the SVF cell population that is responsible for thera-
peutic effects observed after administration.
Adipose tissue resident T regulatory (treg) cells
Treg cells are conventionally described as CD4+ cells pos-
sessing the transcription factor FoxP3 and capable of sup-
pressing T cell activation, dendritic cell maturation,
neutrophil activation, and antibody production. The fun-
damental role of Treg in controlling immunity can be illu-
strated by the fact that genetic mutations associated with
loss of Treg function, such as FoxP3 mutations, are asso-
ciated with autoimmunity in mouse and man [91-93].
Additionally, conditional ablation of the Treg compart-
ment in genetically-engineered mice results in systemic
organ autoimmunity [94]. Numerous autoimmune
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number and/or activity, whereas relapse is associated with
reduction in number and/or activity. Specifically, this has
been demonstrated in multiple sclerosis [95-99], rheuma-
toid arthritis [100-104], and lupus [105-107]. Given the
importance of Treg cells in the control of autoimmunity,
it would be useful to possess sources of Treg cells that are
easily accessible and can be reintroduced into the patient
for immune modulation. It has been previously demon-
strated that high numbers of Treg cells are found in adi-
pose tissue at concentrations much higher than other
peripheral compartments such as blood or spleen [108].
Interestingly, adipose derived Treg contain approximately
100 fold higher concentrations of the immune regulatory
effector cytokine IL-10 [109,110]. It is known that the adi-
pose derived cytokines leptin and TNF-alpha inhibit Treg
proliferation and activity in vivo [111,112]. The local
effects of these cytokines would conceptually, be negated
by liberating Treg from fat tissue followed by systemic re-
administration, resulting in enhanced Treg activity.
Administration of a large number of Treg cells with aug-
mented in vivo proliferative and functional potential may
result in a reduction of the threshold needed to attain tol-
erance to an ongoing immune response. For example,
anti-CD3 antibodies have been reported to induce anti-
gen-specific tolerance, despite the fact that the surge in
Treg numbers was not antigen-specific [113]. Thus one
conceptual advantage of utilizing SVF therapy would be
not only the MSC content, which possesses various regen-
erative properties, but also Treg, which would enhance
anti-inflammatory/tolerance inducing properties. Given
that both MSC and Treg are considered to be tolerance-
promoting, it may be feasible to consider that synergize of
tolerance induction may be occurring when the two cell
populations are co-administered in the form of SVF.
Endothelial progenitor cell (EPC)
Aging and/or damaged blood vessel endothelium is con-
stantly renewed by circulating cells termed endothelial
progenitor cells (EPC). This notion gathered significant
scientific following subsequent to a paper by Asahara et
al. who demonstrated that BM-originating cells expres-
sing VEGFR-2 and CD34 are capable of incorporating
into sites of angiogenesis induced by wire injury or
ischemia [114]. Therapeutic properties of EPC have
been demonstrated in that administration of exogenous
EPC increases vascular repair. This has been shown
using in vitro generated EPC, or bone marrow as a
source of EPC in myocardial infarct [115,116], stroke
[117], lung injury [118-120], liver failure [121-123], and
endothelial injury atherosclerotic models [124,125].
Furthermore, administration of growth factors that sti-
mulate mobilization of bone marrow stem cells and EPC
have demonstrated therapeutic benefit in animal models
of ischemic disease [126,127] as well as endothelial
damage [128]. Clinical trials using EPC or bone marrow
as a source of EPC for cardiovascular conditions
[129-132], have demonstrated some therapeutic benefit,
although work is ongoing.
Historically, the bone marrow has been used as a
source of EPC, however, numerous recent studies have
demonstrated a high content of EPC in adipose tissue
[133,134]. Functional demonstration of adipose EPC was
performed in experiments in which CD34 expressing
cells were sorted for from SVF. This cellular fraction was
demonstrated to induce angiogenesis in immune com-
promised mice that were subjected to hindlimb ischemia.
Mechanistically, the cells were identified as EPC based on
ability to form endothelial colonies when cultured in
vitro [135]. Numerous groups have reported that SVF
contains cellular activity that stimulates angiogenesis, for
example, Sumi et al. showed that administration of SVF
but not adipocytes led to revascularization in the hin-
dlimb ischemia model [136]. Other studies have shown
that not only are EPC-like activities found in SVF [137],
but also that conditioned media from SVF is capable of
stimulating host angiogenesis [138,139]. It is reported
that EPC in the SVF stimulate angiogenesis directly
through differentiating into endothelial cells or through
release of growth factors such as IGF-1, HGF-1 and
VEGF [136,137,139,140]. Although back-to-back compar-
isons of bone marrow and adipose derived EPC for asses-
sing angiogenic potential have not been performed, the
substantially higher concentration of these cells in SVF
supports the investigation of this tissue as a practical cell
source for clinical applications.
Rationale for clinical applications
Given that SVF represents a multi-cellular population
containing MSC, Treg, and EPC, the potential for thera-
peutic utilization would include many conditions that
require regeneration, immune modulation, and possibly
angiogenesis.
We previously reported remission in a patient with
rheumatoid arthritis who was treated with autologous
SVF [29]. Animal studies using the collagen II model of
RA have demonstrated that administration of MSC is
associated with immune modulation [141-143], disease
remission [144,145], and regeneration of cartilage
[5,146]. Additionally, our group and others have
reported that Treg cells are associated with induction of
disease remission [100-102,104,147-151].
Safety data
The study was a retrospective analysis of patients trea-
ted under the practice of medicine under doctor patient
privilege. The protocols were approved by local and
institutional committees and all patients signed
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experimental nature of the treatment. Retrospective
chart analysis of the patients was approved by PEARL
IRB (Indianapolis, Indiana).
Patients received the indicated amount of cells by
intravenous injection (2x10
6 cells per ml diluted in Sal-
ine solution), intra-articular injection (2.5x10
6 cells per
ml in each injured joint, diluted in Saline solution and
the patient’s own serum). Multiple injections of cells
were given to increase the therapeutic efficacy. Follow-
ups were performed for all patients at 1, 3, 6 and 12
months.
SVF cells were isolated and prepared under the guide-
lines of Good Tissue Practices 21 CFR 1271 as relates to
sample screening and processing in the sterile flow
hood, inside of a class 10000 clean room. SVF cells were
isolated by first washing 500 cc of lipoaspirate with PBS
and subsequently, the cells were transferred to 175 ml
sterile centrifuge containers followed by the addition of
collagenase solution for a final concentration of 0.048%.
The centrifuge containers were sealed and placed in an
elliptical shaker and incubated at 37 C for 60-80 min-
utes. The content of the tubes was filtered through a
cell strainer into sterile 50 ml centrifuge tubes and cen-
trifuged for 12 min at 800 rcf. During centrifugation,
SVF cells formed a pellet in the bottom of the container
while the adipocyte layer and debris remained sus-
pended. Following centrifugation, the stromal cells were
resuspended in 5 mL of autologous serum for enzyme
inactivation then washed 2 times with PBS. The fraction
used for intraarticular injection was incubated with buf-
fer to lyse red blood cells and washed once more. All
the cells were aliquoted in cryovials, frozen in liquid
nitrogen and stored until use. Cells were assessed for
viability, endotoxin, and contamination before treatment
was performed. The patient was allowed to heal from
the liposuction for one week. For each treatment ses-
sion, after thawing the cells were rinsed with PBS and
Human AB serum, diluted in saline solution and autolo-
gous serum, loaded into sterile syringes, and then trans-
ported in a controlled temperature cooler accompanied
by the corresponding certificate and delivered to the
physician for infusion.
Thirteen patients with rheumatoid arthritis were trea-
ted with 38-148 million SVF cells intravenously and
intra-articularly (Table 1). Although no hematopoietic
or biological abnormalities were noted, one of the
patients reported facial flushing, fever and myalgia after
a third of four injections. These symptoms all resolved
spontaneously.
Conclusion
These data suggest the safety and feasibility of adminis-
tering adipose SVF intravenously. The uses of adipose
stem cells have been reported in conditions as diverse as
from hearing loss [152], to heart failure [153]. Given the
anti-inflammatory, differentiation ability, and trophic
factor production by SVF, we are hopeful that these
safety data will support ongoing investigation into this
novel and easy to access cell population.
Table 1 Patient Treatments and Safety Outcome
Date of Birth Date Treated Total SVF Dose (x 10
6) & route of injection * Side Effects
(SVF Dose × no. injections)
6/24/1975 3/2/2010 128 IV (32 × 4) Facial flushing, fever, myalgia (resolved after 3
rd injection)
1/15/1950 9/27/2010 120 IV (40 × 3) None
4/10/1954 5/26/2010 90 IV (30 × 3) None
7/4/1967 7/22/2010 60 IV (30 × 2) None
12 IA (6 × 2)
11/29/1950 7/26/2010 60 IV (20 × 3) None
6I A( 6×1 )
7/3/1956 11/3/2010 60 IV (24 × 1, 18 × 2) None
6/1/1942 9/6/2010 90 IV (30 × 3) None
5/3/1940 4/26/2010 80 IV (40 × 2) None
32 IA (16 × 2)
3/20/1941 8/11/2008 54 IV (27 × 2) None
3/25/1942 5/5/2008 108 IV (36 × 3) None
3/5/1963 2/26/2008 99 IV (33 × 3) None
1/15/1966 8/28/2008 90 IV (45 × 2) None
2/9/1952 9/30/2009 48 (30 × 1, 18 × 1) None
* IV = intravenous, IA = intra-articular
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